<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SODIUM DIURIL- chlorothiazide sodium injection </strong><br>Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)<br></p></div>
<h1>Intravenous<br>Sodium Diuril<span class="Sup">®</span><br>(chlorothiazide sodium)
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">Intravenous Sodium DIURIL (chlorothiazide sodium) is a diuretic and antihypertensive. It is 6-chloro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide monosodium salt and its molecular weight is 317.71.
</p>
<p>Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">5</span>ClN<span class="Sub">3</span>NaO<span class="Sub">4</span>S<span class="Sub">2</span> and its structural formula is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d9fa4e6-6516-45cd-a316-292c6a529ecc&amp;name=sod07-0002-01.jpg">
</div>
<p>Intravenous Sodium DIURIL is a sterile lyophilized white powder and is supplied in a vial containing:
</p>
<p>Chlorothiazide sodium equivalent to chlorothiazide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.5 g
</p>
<p>Inactive ingredients: Mannitol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.25 g
</p>
<p>Sodium hydroxide to adjust pH.
</p>
<p>DIURIL (chlorothiazide) is a diuretic and antihypertensive. It is 6-chloro-2<span class="Italics">H</span>-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. Its empirical formula is C<span class="Sub">7</span>H<span class="Sub">6</span>ClN<span class="Sub">3</span>O<span class="Sub">4</span>S<span class="Sub">2</span> and its structural formula is:
</p>
<div class="Figure">
<a name="f02"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d9fa4e6-6516-45cd-a316-292c6a529ecc&amp;name=sod07-0002-02.jpg">
</div>
<p>It is a white, or practically white, crystalline powder with a molecular weight of 295.72, which is very slightly soluble in water, but readily soluble in dilute aqueous sodium hydroxide. It is soluble in urine to the extent of about 150 mg per 100 mL at pH 7.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">The mechanism of the antihypertensive effect of thiazides is unknown. DIURIL (chlorothiazide) does not usually affect normal blood pressure.
</p>
<p>DIURIL (chlorothiazide) affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosage all thiazides are approximately equal in their diuretic efficacy.
</p>
<p>DIURIL (chlorothiazide) increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>.
</p>
<p>After oral use <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours. Following intravenous use of Sodium DIURIL, onset of the diuretic action occurs in 15 minutes and the maximal action in 30 minutes.
</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s4"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics and Metabolism
</h2>
<p class="First">DIURIL is not metabolized but is eliminated rapidly by the kidney; 96 percent of an intravenous dose is excreted unchanged in the urine within 23 hours. The plasma half-life of chlorothiazide is 45-120 minutes. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First">Intravenous Sodium DIURIL is indicated as adjunctive therapy in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> associated with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, and corticosteroid and estrogen therapy.
</p>
<p>Intravenous Sodium DIURIL has also been found useful in <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> due to various forms of renal dysfunction such as <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, acute <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, and <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-4.1"></a><p></p>
<h2>Use in Pregnancy
</h2>
<p class="First">Routine use of diuretics during <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of <span class="product-label-link" type="condition" conceptid="439393" conceptname="Pre-eclampsia">toxemia of pregnancy</span> and there is no satisfactory evidence that they are useful in the treatment of toxemia.
</p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> is due to pathologic causes, just as they are in the absence of pregnancy (see <a href="#s23">PRECAUTIONS, Pregnancy</a>). <span class="product-label-link" type="condition" conceptid="4087149" conceptname="Dependent edema">Dependent edema</span> in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravas-cular volume in this instance is illogical and unnecessary. During <span class="product-label-link" type="condition" conceptid="4128331" conceptname="Pregnancy">normal pregnancy</span> there is <span class="product-label-link" type="condition" conceptid="434004" conceptname="Hypervolemia">hypervolemia</span> which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, rarely <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>. If such <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> causes <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, increased recumbency will often provide relief. Rarely this <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may cause extreme <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s7"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this product or to other sulfonamide-derived drugs.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s8"></a><a name="section-6"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">Intravenous use in infants and children has been limited and is not generally recommended.
</p>
<p>Use with caution in severe <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. In patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, thiazides may precipitate <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>. Cumulative effects of the drug may develop in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.
</p>
<p>Thiazides should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span>.
</p>
<p>Thiazides may add to or potentiate the action of other antihypertensive drugs.
</p>
<p>Sensitivity reactions may occur in patients with or without a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> or bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.
</p>
<p>The possibility of exacerbation or activation of <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span> has been reported.
</p>
<p>Lithium generally should not be given with diuretics (see <a href="#s12">PRECAUTIONS, Drug Interactions</a>).
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s9"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s10"></a><a name="section-7.1"></a><p></p>
<h2>General
</h2>
<p class="First">All patients receiving diuretic therapy should be observed for evidence of fluid or <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>: namely, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4289304" conceptname="Hypochloremic alkalosis">hypochloremic alkalosis</span>, and <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. Serum and urine electrolyte determinations are particularly important when the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> excessively or receiving parenteral fluids. Warning signs or symptoms of fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, irrespective of cause, include dryness of mouth, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pains</span> or <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">cramps</span>, muscular <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span> such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may develop especially with brisk <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, when severe cirrhosis is present or after prolonged therapy.
</p>
<p>Interference with adequate oral electrolyte intake will also contribute to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may cause <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> and may also sensitize or exaggerate the response of the heart to the toxic effects of digitalis (e.g., increased ventricular <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>). <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> may be avoided or treated by use of potassium-sparing diuretics or potassium supplements such as foods with a high potassium content.
</p>
<p>Although any chloride deficit is generally mild and usually does not require specific treatment except under extraordinary circumstances (as in liver disease or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>), chloride replacement may be required in the treatment of <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.
</p>
<p>Dilutional <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> may occur in edematous patients in hot weather; appropriate therapy is water restriction, rather than administration of salt, except in rare instances when the <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> is life-threatening. In actual <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span>, appropriate replacement is the therapy of choice.
</p>
<p><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span> may occur or acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> may be precipitated in certain patients receiving thiazides.
</p>
<p>In diabetic patients dosage adjustments of insulin or oral hypoglycemic agents may be required. <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> may occur with thiazide diuretics. Thus <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus may become manifest during thiazide therapy.
</p>
<p>The antihypertensive effects of the drug may be enhanced in the postsympathectomy patient.
</p>
<p>If progressive <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> becomes evident, consider withholding or discontinuing diuretic therapy.
</p>
<p>Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypo-magnesemia.
</p>
<p>Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> may be evidence of hidden <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span>. Thiazides should be discontinued before carrying out tests for parathyroid function.
</p>
<p>Increases in <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and triglyceride levels may be associated with thiazide diuretic therapy.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s11"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests
</h2>
<p class="First">Periodic determination of serum electrolytes to detect possible <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> should be done at appropriate intervals.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s12"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions
</h2>
<p class="First">When given concurrently the following drugs may interact with thiazide diuretics.
</p>
<dl>
<dt> 
</dt>
<dd>
<span class="Italics">Alcohol, barbiturates, or narcotics</span> - potentiation of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> may occur.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Antidiabetic drugs - (oral agents and insulin)</span> - dosage adjustment of the antidiabetic drug may be required.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Other antihypertensive drugs</span> - additive effect or potentiation.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Corticosteroids, ACTH</span> - intensified <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span>, particularly <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Pressor amines (e.g., norepinephrine)</span> - possible decreased response to pressor amines but not sufficient to preclude their use.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)</span> - possible increased responsiveness to the muscle relaxant.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Lithium</span> - generally should not be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>. Refer to the package insert for lithium preparations before use of such preparations with Sodium DIURIL.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Non-steroidal Anti-inflammatory Drugs</span> - In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when Sodium DIURIL and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="s21"></a><a name="section-7.4"></a><p></p>
<h2>Drug/Laboratory Test Interactions
</h2>
<p class="First">Thiazides should be discontinued before carrying out tests for parathyroid function (see <a href="#s10">PRECAUTIONS, General</a>).
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s22"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Carcinogenicity studies have not been conducted with chlorothiazide.
</p>
<p>Chlorothiazide was not mutagenic <span class="Italics">in vitro</span> in the Ames microbial mutagen test (using a maximum concentration of 5 mg/plate and <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> TA98 and TA100) and was not mutagenic and did not induce mitotic nondisjunction in diploid-<span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Aspergillus nidulans</span>.
</p>
<p>Chlorothiazide had no adverse effects on fertility in female rats at doses up to 60 mg/kg/day and no adverse effects on fertility in male rats at doses up to 40 mg/kg/day. These doses are 1.5 and 1.0 times** the recommended maximum human dose, respectively, when compared on a body weight basis.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s23"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s24"></a><a name="section-7.6.1"></a><p></p>
<p class="First"><span class="Italics">Teratogenic Effects - Pregnancy Category C:</span> Although reproduction studies performed with chlorothiazide doses of 50 mg/kg/day in rabbits, 60 mg/kg/day in rats and 500 mg/kg/day in mice revealed no external abnormalities of the fetus or impairment of growth and survival of the fetus due to chlorothiazide, such studies did not include complete examinations for visceral and skeletal abnormalities. It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman; however, thiazides cross the placental barrier and appear in cord blood. DIURIL should be used during pregnancy only if clearly needed (see <a href="#s5">INDICATIONS AND USAGE</a>).
</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="s25"></a><a name="section-7.6.2"></a><p></p>
<p class="First"><span class="Italics">Nonteratogenic Effects:</span> Chlorothiazide may cause fetal or <span class="product-label-link" type="condition" conceptid="195064" conceptname="Perinatal jaundice due to hepatocellular damage">neonatal jaundice</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and possibly other adverse reactions which have occurred in the adult.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s26"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Because of the potential for serious adverse reactions in nursing infants from Intravenous Sodium DIURIL, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s27"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and effectiveness of Intravenous Sodium DIURIL in pediatric patients have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s28"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">Clinical studies of Intravenous Sodium DIURIL did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see <a href="#s8">WARNINGS</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s29"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The following adverse reactions have been reported and, within each category, are listed in order of decreasing severity.
</p>
<dl>
<dt> 
</dt>
<dd>
<span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive drugs).
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">Pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (intrahepatic <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="29056" conceptname="Sialoadenitis">sialadenitis</span>, cramping, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">gastric irritation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Hematologic:</span> <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">Aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>:</span> <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, necrotizing <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">angiitis</span> (<span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> and <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>), <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span> including <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Metabolic:</span> <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte imbalance</span> (see <a href="#s9">PRECAUTIONS</a>), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">hyperuricemia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasm</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Nervous System/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">Erythema multiforme</span> including <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> including <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Special Senses:</span> Transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4168789" conceptname="Xanthopsia">xanthopsia</span>.
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, renal dysfunction, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, (see <a href="#s8">WARNINGS</a>); <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (following intravenous use).
</dd>
<dt> 
</dt>
<dd>
<span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">Impotence</span>.
</dd>
</dl>
<p>Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.
</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Oak Pharmaceuticals, Inc. at 1-800-932-5676 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s30"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">The most common signs and symptoms observed are those caused by <span class="product-label-link" type="condition" conceptid="4077438" conceptname="Electrolyte depletion">electrolyte depletion</span> (<span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, <span class="product-label-link" type="condition" conceptid="4016089" conceptname="Hypochloremia">hypochloremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>) and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> resulting from excessive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. If digitalis has also been administered, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> may accentuate <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.
</p>
<p>In the event of overdosage, symptomatic and supportive measures should be employed. Correct <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, <span class="product-label-link" type="condition" conceptid="377604" conceptname="Hepatic coma">hepatic coma</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> by established procedures. If required, give oxygen or artificial respiration for respiratory impairment.
</p>
<p>The degree to which chlorothiazide sodium is removed by hemodialysis has not been established.
</p>
<p>The intravenous LD<span class="Sub">50</span> of chlorothiazide in the mouse is 1.1 g/kg.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s31"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Intravenous Sodium DIURIL should be reserved for patients unable to take oral medication or for emergency situations.
</p>
<p>Therapy should be individualized according to patient response. Use the smallest dosage necessary to achieve the required response.
</p>
<p>Intravenous use in infants and children has been limited and is not generally recommended.
</p>
<p>When medication can be taken orally, therapy with DIURIL tablets or oral suspension may be substituted for intravenous therapy, using the same dosage schedule as for the parenteral route.
</p>
<p>Intravenous Sodium DIURIL may be given slowly by direct intravenous injection or by intravenous infusion.
</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4295895" conceptname="Extravasation">Extravasation</span> must be rigidly avoided. Do not give subcutaneously or intramuscularly.</span></p>
<p>The usual adult dosage is 0.5 to 1 g once or twice a day. Many patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> respond to intermittent therapy, i.e., administration on alternate days or on three to five days each week. With an intermittent schedule, excessive response and the resulting undesirable <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> are less likely to occur.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s32"></a><a name="section-10.1"></a><p></p>
<h2>Directions for Reconstitution
</h2>
<p class="First"><span class="Bold">Use aseptic technique. Because Intravenous Sodium DIURIL contains no preservative, a fresh solution should be prepared immediately prior to each administration, and the unused portion should be discarded.</span></p>
<p>Add 18 mL of Sterile Water for Injection to the vial to form an isotonic solution for intravenous injection. Never add less than 18 mL. When reconstituted with 18 mL of Sterile Water, the final concentration of Intravenous Sodium DIURIL is 28 mg/mL. The reconstituted solution is clear and essentially free from visible particles. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use whenever solution and container permit. The solution is compatible with dextrose or sodium chloride solutions for intravenous infusion. Avoid simultaneous administration of solutions of chlorothiazide with whole blood or its derivatives.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s33"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First">Intravenous Sodium DIURIL is a dry, sterile lyophilized white powder usually in plug form, supplied in vials containing chlorothiazide sodium equivalent to 0.5 g of chlorothiazide.
</p>
<p>NDC 76478-711-40.
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s34"></a><a name="section-11.1"></a><p></p>
<h2>Storage
</h2>
<p class="First">Store at 20-25°C (68-77°F). See USP controlled room temperature.
</p>
<p>For single dose only. Use solution immediately after reconstitution (see <a href="#s32">DOSAGE AND ADMINISTRATION, Directions for Reconstitution</a>). Discard unused portion of the reconstituted solution.
</p>
<p><span class="Bold">AKORN</span></p>
<p>Distributed by: <span class="Bold">Akorn, Inc.<br></span>Lake Forest, IL 60045
</p>
<p><span class="Bold">OAK</span></p>
<p>Mfd. for: <span class="Bold">Oak Pharmaceuticals, Inc.</span></p>
<p><span class="Sup">®</span> Registered trademark of Merck &amp; Co., Inc.<br>Whitehouse Station, NJ 08889, U.S.A.
</p>
<p>** Calculations based on a human body weight of 50 kg.
</p>
<p>OPCH00N   Rev. 05/12<br>750-06619-1
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s35"></a><a name="section-12"></a><p></p>
<p class="First">Principal Display Panel Text for Container Label:
</p>
<p>NDC 76478-711-40 Single Dose Vial
</p>
<p>Intravenous
</p>
<p>Sodium Diuril®
</p>
<p>(chlorothiazide sodium)
</p>
<p>0.5 g
</p>
<p>Chlorothiazide Equivalent
</p>
<p>Rx only Oak Logo
</p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel Text for Container Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d9fa4e6-6516-45cd-a316-292c6a529ecc&amp;name=sod07-0002-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s36"></a><a name="section-13"></a><p></p>
<p class="First">Principal Display Panel Text for Carton Label:
</p>
<p>NDC 76478-711-40  12 Vials
</p>
<p>Intravenous  Rx only
</p>
<p>Sodium Diuril® (chlorothiazide sodium)
</p>
<p>0.5 g
</p>
<p>Chlorothiazide Equivalent
</p>
<p>For preparation of Intravenous Solutions
</p>
<p>Store at 20-25°C (68-77°F). See USP Controlled Room Temperature Oak Logo
</p>
<div class="Figure">
<a name="f04"></a><img alt="Principal Display Panel Text for Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d9fa4e6-6516-45cd-a316-292c6a529ecc&amp;name=sod07-0002-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SODIUM DIURIL 		
					</strong><br><span class="contentTableReg">chlorothiazide sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:76478-711</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>chlorothiazide sodium</strong> (chlorothiazide) </td>
<td class="formItem">chlorothiazide</td>
<td class="formItem">0.5 mg  in 18 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:76478-711-40</td>
<td class="formItem">12  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">18 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA011145</td>
<td class="formItem">10/03/1958</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)
							(968937719)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>aebe3b0a-b212-49cf-ae95-73f6f4be2e7f</div>
<div>Set id: 1d9fa4e6-6516-45cd-a316-292c6a529ecc</div>
<div>Version: 4</div>
<div>Effective Time: 20120810</div>
</div>
</div> <div class="DistributorName">Oak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)</div></p>
</body></html>
